Henry Schein Has Agreed To Acquire A Majority Interest In TriMed, A Developer Of Solutions For Orthopedic Treatment Of Lower Extremities (Foot And Ankle) And Upper Extremities (Primarily Hand And Wrist); Deal Terms Were Not Disclosed
Portfolio Pulse from Benzinga Newsdesk
Henry Schein (HSIC) has agreed to acquire a majority interest in TriMed, a company specializing in orthopedic solutions for lower and upper extremities. The financial terms of the deal were not disclosed. TriMed reported net sales of about $48 million in 2022. The completion of the transaction is subject to regulatory approvals and closing conditions, with an expected close in the first quarter of 2024.
December 20, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Henry Schein's acquisition of TriMed could enhance its portfolio in orthopedic solutions, potentially leading to increased market share and revenue growth in the long term.
The acquisition of TriMed is likely to have a positive impact on Henry Schein's stock in the short term due to the expansion of its product portfolio and potential for revenue growth. However, since the deal terms were not disclosed and the acquisition is expected to close in 2024, the immediate financial impact is uncertain. The positive score reflects the strategic nature of the acquisition rather than immediate financial benefits.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100